IFNAR1 and neoplasm: To test whether a CD8+ T cell mediated anti-tumour component contributes to the overall therapeutic effect of VSV-GP in the permissive LLC1-IFNAR1−/− tumour, CD8+ T cells were depleted using a monoclonal antibody.